



Kwang-Mook Jung and Daniele Piomelli

Contents

| | |
|--|------|
| Brief History | 2130 |
| The Endocannabinoid System | 2132 |
| Cannabinoid Receptors | 2132 |
| 2-Arachidonoyl- <i>sn</i> -Glycerol (2-AG) | 2134 |
| Anandamide | 2139 |
| Additional Endogenous Cannabinoid Ligands | 2143 |
| Cannabinoid-Based Therapeutics | 2144 |
| CB ₁ Receptor Agonists | 2145 |
| CB ₁ Receptor Antagonists | 2145 |
| CB ₂ Receptor Agonists | 2146 |
| Endocannabinoid Deactivation Inhibitors | 2147 |
| Outlook | 2149 |
| References | 2149 |

Abstract

The intoxicating and medicinal properties of cannabis have been known since the human species domesticated the plant, at least 11,000 years before present. Its psychotropic constituent, (–)- *trans*- Δ^9 -tetrahydrocannabinol (Δ^9 -THC), exerts its pharmacological effects by binding to selective receptors present on the surface of most cells of the human body, including neurons. These receptors are normally

K.-M. Jung

Department of Anatomy and Neurobiology, University of California, Irvine, CA, USA

D. Piomelli (✉)

Department of Anatomy and Neurobiology, University of California, Irvine, CA, USA

Department of Pharmaceutical Sciences, University of California, Irvine, CA, USA

Department of Biological Chemistry, University of California, Irvine, CA, USA

e-mail: piomelli@uci.edu

engaged by a family of lipid-derived mediators, called endocannabinoids, which participate in the regulation of a diversity of physiological functions, including pain, mood, hunger, and memory. The endocannabinoid system (ECS) is comprised of two lipid-derived ligands, anandamide (arachidonoyl ethanolamide) and 2-arachidonoyl-*sn*-glycerol (2-AG), enzymes and transporters that control their formation and deactivation, and receptors (CB₁ and CB₂) that transduce their actions. All key components of the ECS are found in the brain and spinal cord but also in most if not all peripheral organs and tissues.

In this chapter, we outline current views on how endocannabinoid substances are produced, act on cannabinoid receptors, and are deactivated in the brain. In addition, we review progress on the development of pharmacological agents that interfere with endocannabinoid deactivation and discuss their potential utility in the treatment of disease.



Keywords

2-Arachidonoyl-*sn*-glycerol (2-AG) · Bioactive 2-AG metabolites · Enzymatic steps · Formation and deactivation · 2-AG signalosome · Anandamide · Anxiety · Cancer · Cannabinoids · CB₁ receptor agonists · CB₁ receptor antagonists · CB₂ receptor agonists · Chemical structures · Cannabis addiction · Endocannabinoid system · Cannabinoid receptors · Deactivation inhibitors · Fatty acid amide hydrolase (FAAH) · Monoacylglycerol lipase (MGL) · *N*-acyl transferase (NAT) activity · *N*-acyl ethanolamine acid amidase (NAAA) · Perisynaptic annulus · Phospholipase C (PLC) · Phospholipase D (PLD) · Schizophrenia · Tetrahydrocannabinol




Brief History

The intoxicating and medicinal properties of cannabis have been known since the human species domesticated the plant, at least 11,000 years before present. The chemical constituent responsible for the majority of such properties – the terpenophenolic compound(–) *trans*- Δ^9 -tetrahydrocannabinol (Δ^9 -THC) – was first identified in the early 1940s by American chemist Roger Adams, who also devised its first synthesis (Adams 1942). This work was soon confirmed by others (Wollner et al. 1942) and completed in 1964 by Raphael Mechoulam (Gaoni and Mechoulam 1964), who defined its precise structure (Fig. 1a). Despite these advances, the mechanism of action of Δ^9 -THC was strongly debated until 1988, when William Devane and Allyn Howlett discovered that synthetic molecules designed to mimic its effects, such as the compound CP-55,940 (Fig. 1b), bind to unique receptive sites and engage G proteins to inhibit adenylyl cyclase activity in brain tissue (Devane et al. 1988). The subsequent mapping of these binding sites in the rat central nervous system (CNS) (Herkenham et al. 1990) and the molecular cloning of the first cannabinoid receptor gene (Matsuda et al. 1990), now called CB₁, provided definitive evidence that the mammalian brain contains a selective

A. Phytocannabinoids



B. Synthetic Cannabinoids



C. Endocannabinoids





Fig. 1 Chemical structures of representative ligands for cannabinoid receptors. (a) Two terpene-like chemicals present in the *Cannabis* resin. Δ^9 -Tetrahydrocannabinol (Δ^9 -THC) is responsible for the majority of the psychotropic effects of the drug; it acts by binding to G protein-coupled cannabinoid receptors in the brain and other tissues of the body. Cannabidiol displays a distinct set of pharmacological properties (e.g., antipsychotic and antiepileptic), which do not involve cannabinoid receptor activation. (b) Synthetic CB_1 receptor agonists. CP-55,940 and Win-55,212-2 (developed by pharmaceutical companies Pfizer and Winthrop, respectively) and JWH018 (originally synthesized by medicinal chemist J.W. Huffman) are cannabinoid receptor agonists. CP-55,940 and Win-55,212-2 are widely used experimentally, while JWH018 is a component of street drugs such as “Spice.” (c) The two primary endogenous activators of cannabinoid receptors. 2-AG and anandamide are produced on demand through cleavage of membrane lipid precursors and are involved in various short-range signaling processes including several forms of synaptic plasticity

cell-surface receptor that recognizes Δ^9 -THC and underpins many of its biological actions. Shortly after the cloning of CB_1 , a second G protein-coupled receptor, CB_2 , was identified in lymphocytes and other immune cells (Munro et al. 1993).

In the years that followed, the obligatory role of cannabinoid receptors in mediating the effects of Δ^9 -THC and other cannabimimetic (“cannabis-like”) substances was unambiguously demonstrated using selective pharmacological tools (receptor agonists and antagonists) as well as genetic mouse models (mutant mice lacking the CB_1 and CB_2 receptor genes, *cnr1* and *cnr2*) (for reviews, see Kano et al.

2009; Chevaleyre et al. 2006; Freund et al. 2003). Meanwhile, the discovery of cannabinoid (CB) receptors had launched a search for endogenous substances that might interact with these proteins. This quest culminated in the isolation of two lipid-derived molecules – anandamide (arachidonylethanolamide) in 1992 (Devane et al. 1992) and 2-arachidonoyl-*sn*-glycerol (2-AG) in 1995 (Sugiura et al. 1995; Mechoulam et al. 1995) – by the laboratories of Mechoulam and Takayuki Sugiura. Many neuroscientists – accustomed to studying conventional water-soluble neurotransmitters – were initially surprised by the lipid nature of these compounds. Skepticism was eventually overcome, however, by the elucidation of the compounds' unique biogenesis (Di Marzo et al. 1994; Stella et al. 1997), the demonstration of their “on-demand” formation and release in live brain preparations (Di Marzo et al. 1994; Stella et al. 1997; Giuffrida et al. 1999), and the progressive accumulation of evidence indicating that they function as local regulators of synaptic activity, rather than typical transmitters (for reviews, see Piomelli 2003; Piomelli et al. 2007) (more on this point later in the chapter).

The Endocannabinoid System


The endocannabinoid system is comprised of two lipid-derived messengers (the endocannabinoids anandamide and 2-AG), proteins that control their formation and deactivation, and cell-surface receptors (CB₁ and CB₂) that transduce their actions. The key components of endocannabinoid signaling are found in most mammalian organ systems, including the brain.

Cannabinoid Receptors

CB₁ and CB₂ receptors exhibit 48% amino acid sequence identity and signal through the transducing G proteins, G_i and G_o (for reviews, see Mackie 2006; Freund et al. 2003). The binding of Δ⁹-THC and other cannabinoid agonists to these receptors causes inhibition of adenylyl cyclase activity, closing of certain voltage-gated calcium channels, opening of inwardly rectifying potassium channels, and stimulation of various protein kinases (Mackie 2006). In the brain, where CB₁ is primarily localized to axon terminals, two important consequences of its activation are the suppression of neuronal excitability (via increase of K⁺ channel activity) and the reduction of neurotransmitter release (via inhibition of Ca²⁺ channel activity) (Fig. 2).

CB₁ receptor expression is greatest in brain structures that are most implicated in the psychoactive effects of *Cannabis*. In humans and other mammals, high concentrations of CB₁ are found in the neocortex, hippocampus, basal ganglia, and cerebellum. Substantial receptor levels are also present in the basolateral amygdala, hypothalamus, brain stem, and spinal cord (Mackie 2006). CB₁ is also found outside the brain and spinal cord. Functionally significant amounts of the receptor are found in the small intestine, liver, white adipose tissue, pancreas, and skeletal muscle,

Fig. 2 CB₁ receptor signaling in the brain. CB₁ receptors are present in nerve terminals of excitatory (glutamatergic), inhibitory (GABAergic), and modulatory (e.g., serotonergic) neurons of the brain. By recruiting G proteins, CB₁ increases the activity of potassium (K⁺) channels (reducing neuronal excitability) and decreases activity of calcium (Ca²⁺) channels (inhibiting neurotransmitter release). Additionally, CB₁ inhibits adenylyl cyclase (lowering intracellular cyclic AMP levels) and stimulates various protein kinases, including mitogen-activated protein kinases (MAPKs) and focal adhesion kinase, leading to phosphorylation of synaptic proteins



where its presence reflects the pervasive influence exerted by the endocannabinoids on energy balance and peripheral metabolism (for reviews, see DiPatrizio and Piomelli 2012, 2015).

Activation of CB₁ receptors initiates a process of desensitization that eventually renders subjects exposed to Δ^9 -THC and other cannabinoid agonists tolerant to the central and peripheral effects of these drugs (for a review, see González et al. 2005). This process can also occur in humans: positron emission tomography studies have shown that chronic cannabis use causes a downregulation of CB₁ receptors in cortical regions of the brain and that abstinence reverses this effect (Hirvonen et al. 2012).

In addition to CB₁, the brain also contains a small number of CB₂ receptors, which are probably localized to neurons and microglia (Mackie 2006). However, this receptor subtype is expressed at much higher levels in cells of the peripheral immune system, including monocytes and monocyte-derived cells such as macrophages, osteoclasts, and osteoblasts (Mackie 2006). These cells also express CB₁, albeit to a lesser extent than CB₂, with both receptor types exerting a broad spectrum of modulatory effects on cytokine release, apoptosis, and cell migration.

2-Arachidonoyl-*sn*-Glycerol (2-AG)

2-AG and anandamide are the two primary endocannabinoid substances produced in mammalian tissues (Fig. 1c). Though other endogenous lipid-derived cannabinoid receptor ligands have been isolated, only 2-AG and anandamide have been consistently shown to meet three key conditions that define a neurotransmitter: activity-dependent release from neurons, modulation of synaptic transmission via activation of cell-surface receptors, and rapid deactivation (Piomelli 2003; Piomelli et al. 2007).

2-AG Formation and Degradation

At the molecular level, we understand 2-AG much better than we do anandamide. The metabolism of this fatty acyl ester, illustrated in Fig. 3, starts with the cleavage




Fig. 3 Enzymatic steps involved in 2-AG formation and degradation. In cellular membranes, phospholipase C (e.g., $PLC-\beta$) converts phosphatidylinositol-4,5-bisphosphate (PIP_2) into 1,2-diacylglycerol (DAG). DAG is hydrolyzed by diacylglycerol lipase ($DGL-\alpha$) forming the endocannabinoid 2-AG. Alternatively, 2-AG could be produced through serial hydrolyses of phospholipids by phospholipase A_1 (PLA_1) and lyso-PLC activities. 2-AG is subjected to hydrolytic cleavage catalyzed either by monoacylglycerol lipase (MGL) or α/β -hydrolase domain-6 ($ABHD-6$). Additionally, 2-AG can be oxygenated by cyclooxygenase-2 ($Cox-2$) to yield a family of non-endocannabinoid prostaglandin (PG) glycerol esters

of a membrane phospholipid, phosphatidylinositol-4,5-bisphosphate (PIP₂), and ends with the generation of the free fatty acid, arachidonic acid. The first steps in this pathway are sequentially catalyzed by two lipid hydrolases, phospholipase C (PLC) and diacylglycerol lipase (DGL), which are both localized to dendritic spines of excitatory synapses (Stella et al. 1997; Katona et al. 2006). PLC converts PIP₂ into 1,2-diacylglycerol (1,2-DAG) (Bennett et al. 1988). This reaction is stimulated by agonist-bound G_q protein-coupled receptors (e.g., type-1 metabotropic glutamate receptors, mGluR5) and in brain tissue is mediated by the β and ϵ isoforms of PLC (PLC- β and PLC- ϵ) (Jung et al. 2005). 1,2-DAG regulates the activity of protein kinase C and other cellular effectors but also serves as substrate for two DGL isoforms (DGL- α and DGL- β), which cleave 1,2-DAG to produce 2-AG (Stella et al. 1997; Bisogno et al. 2003). Of note, 1,2-DAG can also be transformed by diacylglycerol kinase into phosphatidic acid, another intracellular second messenger (for a review, see Shulga et al. 2011).

It is common for lipid-derived messengers to be produced through multiple biogenetic routes (Piomelli et al. 2007). Another pathway that may contribute to 2-AG production involves phospholipase A₁ (PLA₁). This enzyme cleaves membrane phospholipids at the *sn*-1 position, forming arachidonic acid-containing lysophospholipids that are subsequently converted into 2-AG by a lyso-PLC activity (Pete et al. 1994) (Fig. 3).

After diffusing out of the dendritic spine, newly formed 2-AG reaches axon terminals where it encounters both CB₁ receptors, which are responsible for its presynaptic actions, and the enzyme monoacylglycerol lipase (MGL), which interrupts such actions (Fig. 4). MGL is a ubiquitous serine hydrolase that converts monoacylglycerols such as 2-AG into fatty acid and glycerol (Fig. 3). It was first molecularly characterized in adipocytes, where it catalyzes the last step in triacylglycerol hydrolysis (lipolysis) (Karlsson et al. 1997), and was later shown to be also responsible for 2-AG deactivation in the brain (Dinh et al. 2002). This conclusion is supported by results obtained with pharmacological inhibitors and genetically modified mice that either lack or overexpress MGL (Hohmann et al. 2005; Jung et al. 2012a). In the brain, MGL is primarily found in axon terminals and is almost equally distributed between the cytosol and the inner aspect of the presynaptic cell membrane (Dinh et al. 2002, 2004; Gulyas et al. 2004). This localization suggests that MGL may readily gain access to the pool of 2-AG that interacts with CB₁ receptors in axon terminals and, therefore, may efficiently catalyze the hydrolysis of this compound at its main site of action. Studies in a neural cell line have provided evidence that the MGL-mediated degradation of 2-AG is driven by the subsequent condensation of arachidonic acid with coenzyme A (Beltramo and Piomelli 2000), a pivotal step in phospholipid remodeling catalyzed by acyl-CoA synthetase (for a review, see Farooqui et al. 2000).

MGL accounts for about 85% of the total 2-AG hydrolase activity present in the rodent brain (Dinh et al. 2004). The remainder have been attributed to two additional serine lipases, α/β hydrolase domain-containing protein (ABHD)-6 and ABHD-12 (Blankman et al. 2007), which are also able to catalyze the hydrolysis of 2-AG *in vitro*. The role of ABHD-6 in terminating the actions of 2-AG remains uncertain.




Fig. 4 Molecular architecture of 2-AG signaling in the brain. Cell membrane-associated lipid hydrolases phospholipase C- β (*PLC- β*) and diacylglycerol lipase- α (*DGL- α*) are involved in the biosynthesis of 2-AG. On-demand activation of receptors such as metabotropic glutamate receptor subtype 5 (*mGluR5*) may trigger the biosynthetic pathway. Monoacylglycerol lipase (*MGL*) hydrolyzes and deactivates 2-AG, terminating its effects

Data supporting such a role have been obtained for ABHD-6, the inhibition of which prolongs the effects of 2-AG at brain synapses (Jung et al. 2012a; Marrs et al. 2010). By contrast, ABHD-12 was shown to be primarily involved in the degradation of lysophosphatidylserine (Blankman et al. 2013), a phospholipid that is not directly involved in endocannabinoid signaling.

The 2-AG Signalosome

Strictly confined to an area of the dendritic spine that is adjacent to the postsynaptic density (PSD) – the so-called perisynaptic annulus – the 2-AG signalosome is a multimolecular protein complex that joins in a single functional unit, held together by scaffolding Homer proteins, three key players in 2-AG production: *mGluR5*, *PLC- β* , and *DGL- α* (Katona et al. 2006; Jung et al. 2007, 2012b) (Fig. 5). When glutamate released by excitatory terminals binds to *mGluR5*, the physical proximity of this protein to *PLC- β* and *DGL- α* enables 2-AG to be generated in large amounts within this focal area. Newly formed 2-AG leaves the postsynaptic membrane to activate *CB₁* receptors on adjacent nerve terminals, causing in turn a reduction in calcium channel activity and glutamate release. The fraction of 2-AG that reaches the terminals and activates *CB₁* may be then rapidly hydrolyzed by *MGL*, while the 2-AG that remains associated with the spine might be eliminated by *ABHD-6*, which




Fig. 5 The 2-AG signalosome at excitatory brain synapses. This supramolecular complex, selectively localized to the perisynaptic zone of the dendritic spine, connects in a single functional unit three key proteins involved in 2-AG production – mGluR5 metabotropic glutamate receptors, phospholipase C- β (PLC- β), and diacylglycerol- α (DGL- α). Evidence suggests that these proteins are held together by the scaffolding proteins Homer-cc and Shank. Fragile X mental retardation protein (FMRP) may help target DGL- α to the 2-AG signalosome, possibly by positioning the DGL- α or Homer message(s) in specific subcellular nanodomains (coupling). It is hypothesized that expression of multimerization-incompetent Homer1a isoform could cause a dissociation of the 2-AG signalosome (uncoupling). The proximity of mGluR5 to PLC- β and DGL- α allows for the rapid accumulation of 2-AG, which travels across the synaptic cleft to activate CB₁ receptors on axon terminals. The 2-AG that reaches presynaptic terminals may be quickly hydrolyzed by monoacylglycerol lipase (MGL), while the 2-AG that fails to reach the terminals may be degraded by α/β hydrolase domain-containing protein 6 (ABHD-6). AMPAR AMPA receptors, NMDAR NMDA receptors, PSD postsynaptic density

is localized postsynaptically (Marrs et al. 2010; Jung et al. 2012b) (Fig. 5). The 2-AG signalosome was identified at excitatory synapses of the ventral striatum and prefrontal cortex (Jung et al. 2012a) but is likely to be present in other regions of the mammalian CNS (Mátyás et al. 2008; Nyilas et al. 2009). The identification of the 2-AG signalosome (Jung et al. 2012a) provides an unusual example of point-to-point lipid signaling. In contrast to classical autacoid-type signaling (e.g., by diffusible eicosanoids), this signaling modality requires that the enzymes needed to produce 2-AG be arranged in such a way as to make 2-AG-mediated retrograde transmission rapid and efficient (Fig. 6).




Fig. 6 2-AG as a point-to-point regulator of synaptic activity. 2-AG signaling at excitatory synapses of the brain provides a first example of point-to-point-type lipid signaling. In contrast to classical autacoid-type lipid signaling (e.g., via diffusible prostaglandins) (a), point-to-point signaling requires that the proteins essential for the formation and deactivation of 2-AG are spatially arranged to make signaling both rapid and efficient (b)

The structural arrangement outlined above has been documented at excitatory synapses, which contain relatively low levels of CB_1 receptors (Marsicano and Lutz 1999). Inhibitory synapses formed by cholecystokinin-containing GABAergic interneurons – where retrograde signaling has been also demonstrated (for reviews, see Castillo et al. 2012 and Katona and Freund 2012) and CB_1 is present in large numbers (Katona et al. 1999) – are likely to control endocannabinoid signaling through different mechanisms, which remain unknown.

Bioactive 2-AG Metabolites

The sequential action of PLC, DGL, and MGL contributes to the release of free (nonesterified) arachidonic acid from membrane phospholipids (Allen et al. 1992; Bell et al. 1979) (Fig. 3). Like other polyunsaturated fatty acids, free arachidonate is either immediately reinserted into membrane phospholipids (part of a process known as “phospholipid remodeling”) or utilized for the production of the eicosanoids, a large family of cyclooxygenase metabolites that include prostaglandins, thromboxanes, and leukotrienes (Piomelli et al. 2007). These are important bioactive lipids that control the neural response to psychological stress, body temperature, and energy homeostasis, among other processes (for reviews, see Piomelli et al. 2007;

Harizi et al. 2008). 2-AG itself can be oxygenated by cyclooxygenase-2 (Cox-2) to yield a family of prostaglandin glyceryl esters, which do not bind cannabinoid receptors yet display interesting biological activities (Kozak et al. 2000). It appears that neural cells can steer 2-AG toward alternative fates of metabolic activation (e.g., formation of prostaglandin glyceryl esters) or deactivation (e.g., hydrolysis followed by arachidonic acid reesterification into phospholipids or Cox-2-dependent oxidation). The selection between these paths is likely to depend on the cells' signaling needs, but how such selection is made and enforced is entirely unknown.

Anandamide

Figure 7 illustrates the main molecular pathways involved in the formation and degradation of anandamide. In contrast with 2-AG, the reactions leading to the production of this endocannabinoid are relatively unprecedented in lipid biochemistry, and anandamide and other members of its chemical family – the amides of ethanolamine with long-chain fatty acids (known as *N*-acylethanolamines or fatty acid ethanolamides) – were initially dismissed as being terminal products of post mortem tissue degradation rather than physiologically meaningful signaling molecules (Schmid et al. 1995). The functional significance – and indeed the very existence (Kempe et al. 1996) – of anandamide remained controversial until the mechanisms underlying the production and deactivation of this compound were outlined using primary cultures of rat brain neurons (Cadas et al. 1996, 1997; Di Marzo et al. 1994) and its activity-dependent release in the CNS of freely moving rats was demonstrated by using a combination of *in vivo* microdialysis and gas chromatography/mass spectrometry (Giuffrida et al. 1999).

Anandamide Formation

Three interconnected enzyme pathways have been implicated in anandamide production (Fig. 7). The “canonical route,” shown in the center of the figure, was elaborated in 1994–1997 (Cadas et al. 1996, 1997; Di Marzo et al. 1994). According to this model, anandamide is released by hydrolysis of the phospholipid precursor, *N*-arachidonoyl-phosphatidylethanolamine (*N*-arachidonoyl-PE), which is catalyzed by a phospholipase D (PLD) that preferentially recognizes *N*-acyl-substituted PE species (collectively called NAPEs) over other more common phospholipids (for a review, see Ueda et al. 2013). A unique PLD that selectively hydrolyzes NAPEs, including *N*-arachidonoyl-PE, was molecularly cloned (Ueda et al. 2013) and its structure was recently resolved by X-ray crystallography (Magotti et al. 2015). Nevertheless, its physiological role in anandamide formation remains to be fully elucidated (for a review, see Piomelli 2014).

The levels of the anandamide precursor, *N*-arachidonoyl-PE, are vanishingly low in resting neurons but quickly increase when the neurons are exposed to stimuli that elevate intracellular calcium concentrations (Cadas et al. 1996, 1997; Di Marzo et al. 1994; Stella and Piomelli 2001). For *N*-arachidonoyl-PE to be produced, a sequence of two distinct enzyme-mediated reactions must occur. First, arachidonic acid must




Fig. 7 Enzymatic steps involved in anandamide formation and degradation. The canonical route of anandamide biosynthesis is shown in the center. According to this model, anandamide is released by hydrolysis of the phospholipid precursor, *N*-arachidonoyl-phosphatidylethanolamine (*N*-arachidonoyl-PE), catalyzed by a phospholipase D (*PLD*). *N*-arachidonoyl-PE is produced through a two-step reaction in which arachidonic acid (*AA*) is transferred from the *sn*-2 position of a phospholipid to the *sn*-1 position of lysophosphatidylcholine (*PC*), producing diarachidonoyl-PC. The *sn*-1 arachidonoyl chain of diarachidonoyl-PC is then transferred to the free amino group of PE, generating *N*-arachidonoyl-PE. Two additional routes of anandamide biosynthesis have been proposed. *Left*: an as-yet-uncharacterized phospholipase C (*PLC*) converts *N*-arachidonoyl-PE into phospho-anandamide, which is then dephosphorylated by a phosphatase forming anandamide. *Right*: *N*-arachidonoyl-PE is hydrolyzed by α/β hydrolase domain-containing protein 4 (*ABHD-4*), forming glycerophospho-anandamide, which generates anandamide after losing the glycerophosphate group. Anandamide is degraded intracellularly by the serine amidase, fatty acid amide hydrolase (*FAAH*)

be transferred from the *sn*-2 position of various phospholipids, where it normally resides, to the *sn*-1 position of lysophosphatidylcholine, producing a low-abundance phosphatidylcholine species that incorporates arachidonic acid at both *sn*-1 and *sn*-2 positions (Fig. 7). The newly generated diarachidonoyl-phosphatidylcholine gives quickly away its *sn*-1 acyl chain to the free amino group of phosphatidylethanolamine, generating *N*-arachidonoyl-PE. This reaction is catalyzed by the *N*-acyl transferase (NAT) activity of type-e cytosolic phospholipase A₂ (Ogura et al. 2016) (Fig. 7). The sequential formation of diarachidonoyl-phosphatidylcholine and *N*-arachidonoyl-PE is strictly calcium-dependent and represents the rate-limiting step in the production of anandamide in intact neurons (Cadas et al. 1997).

Two detours from the canonical biosynthesis of anandamide have been proposed, both of which utilize *N*-arachidonoyl-PE as a starting point and substitute NAPE-PLD with one or more lipid hydrolases (Fig. 7). Macrophages exposed to the bacterial toxin, lipopolysaccharide (LPS), emit a burst of lipid mediators that include anandamide (Liu et al. 2006) and other bioactive derivatives of arachidonic acid (Dennis et al. 2010). This response is unlikely to be mediated by NAPE-PLD – the expression of which is, in fact, strongly suppressed by LPS (Zhu et al. 2011) – but rather appears to require the consecutive action of two as-yet-uncharacterized enzymes: a PLC activity that converts *N*-arachidonoyl-PE into phospho-anandamide and a phosphatase activity that cleaves the latter into anandamide and free phosphate (Liu et al. 2006) (Fig. 7). In addition to this PLC-initiated mechanism, *N*-arachidonoyl-PE may be also subjected to a double deacylation at its *sn*-1 and *sn*-2 positions, catalyzed by the enzyme ABHD-4, to produce glycerophospho-anandamide (Simon and Cravatt 2006). This intermediate may be transformed into anandamide by cleavage of its phosphodiester bond, catalyzed by the phosphodiesterase GDE1, and release of glycerol phosphate (Simon and Cravatt 2008).

The existence of multiple routes of anandamide production might reflect the diversity of physiological stimuli that are able to mobilize this endocannabinoid – which include, in neural cells, membrane depolarization, intracellular calcium transients, dopamine D₂, or oxytocin receptor activation (Di Marzo et al. 1994; Giuffrida et al. 1999; Liu et al. 2006; Lourenço et al. 2011; Steffens et al. 2003; Stella and Piomelli 2001; Wei et al. 2015). However, it is important to point out that each of the three pathways described above attributes a central place to the enzyme system that catalyzes the formation of diarachidonoyl-PC and *N*-arachidonoyl-PE. Since this is the only system that directs NAPE hydrolysis toward the selective production of anandamide, its full molecular characterization will be crucial to fully understand this important branch of the endocannabinoid signaling system.

Anandamide Deactivation

After release into the extracellular space, anandamide acts as a partial agonist at CB₁ receptors and is subsequently deactivated by cellular uptake and intracellular hydrolysis (Fig. 8). The molecular mechanisms utilized by neural cells to degrade anandamide are reasonably well understood. Anandamide is a preferred endogenous substrate for the intracellular serine amidase, fatty acid amide hydrolase (FAAH), a member of the amidase signature family of enzymes that catalyzes the cleavage of various long-chain fatty acyl amides (Cravatt et al. 1996; Desarnaud et al. 1995; Hillard et al. 1995; Ueda et al. 1995a). Other lipid hydrolases, such as *N*-acylethanolamine acid amidase (NAAA) (for a review, see Ueda et al. 2010) and acid ceramidase (AC) (Li et al. 1998; for a review, see Park and Schuchman 2006), are also able to hydrolyze lipid amide bonds but show little or no affinity for anandamide and are unlikely to play an important role in its deactivation. Consistent with this view, interventions that interrupt FAAH activity cause a profound enhancement in anandamide-mediated signaling at CB₁ receptors (Cravatt et al. 2001; Kathuria et al. 2003), whereas blockade of NAAA or AC exerts no such effect (Realini et al. 2013; Sasso et al. 2013).




Fig. 8 Molecular players in the endocannabinoid system: anandamide. *N*-acyl-phosphatidyl-ethanolamine-selective phospholipase D (*NAPE-PLD*) and an unknown *N*-acyl transferase (*NAT*) may be involved in the biosynthesis of anandamide. Fatty acid amide hydrolase (*FAAH*) hydrolyzes and deactivates the compound

FAAH is expressed at high levels throughout the CNS. In situ hybridization studies in the rat have shown that *FAAH* transcription is highest in the neocortex and hippocampus; intermediate in the cerebellum, thalamus, olfactory bulb, and striatum; and lowest in the hypothalamus, brain stem, and pituitary gland (Thomas et al. 1997). Immunohistochemical experiments largely confirmed this distribution, showing that principal neurons in the cerebral cortex, hippocampus, cerebellum, and olfactory bulb have the strongest expression of *FAAH* protein (Egertová et al. 1998). Many *FAAH*-positive neurons in the brain are found in proximity of nerve terminals that contain CB_1 receptors, supporting a role for *FAAH* in anandamide deactivation (Egertová et al. 2003; for a review, see McKinney and Cravatt 2005). There are, however, several regions of the brain where no such correlation can be demonstrated. This discrepancy may reflect the participation of *FAAH* in the catabolism of

“paracannabinoid” (from Greek, *pará* “around”) lipid amides such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), which are endogenous ligands for the nuclear receptor PPAR- α (peroxisome proliferator-activated receptor type- α) (Fu et al. 2003; for reviews, see LoVerme et al. 2005; DiPatrizio and Piomelli 2015). Supporting this idea, pharmacological inhibition of FAAH activity or genetic disruption of the *faah* gene results in marked increases in the levels of these FAEs, along with anandamide’s (Cravatt et al. 2001).

FAAH is housed on intracellular organelle membranes of dendritic spines (Gulyas et al. 2004). This localization raises the question of how anandamide might be able to cover the distance between its site of action (CB₁ receptors on axon terminals) and its site of degradation (organelles in postsynaptic spines). There is evidence that this process is mediated through a selective carrier system present in both neurons and glial cells. This system exhibits three identifying features of a carrier-mediated transport process: first, saturation kinetics, plots of the initial rate of anandamide accumulation against extracellular anandamide concentrations yield apparent Michaelis constants that are similar to those measured for other known neurotransmitter uptake systems (Beltramo et al. 1997); second, substrate specificity, rat brain neurons and other cells in culture internalize anandamide but not closely related analogs (Beltramo et al. 1997); and third, selective inhibition, a variety of natural and synthetic compounds, including chiral analogs of anandamide, block [³H] anandamide transport in a competitive and stereospecific manner (Piomelli et al. 1999). Moreover, anandamide transport does not require FAAH, since pharmacological or genetic FAAH ablation does not interrupt its activity (Beltramo et al. 1997; Fegley et al. 2004). However, the molecular mechanism(s) underpinning anandamide transport remains disputed.

Anandamide can be also metabolized by cyclooxygenase-2, lipoxygenases, and cytochrome P450 to oxygen-containing products that display significant biological activities at as-yet-unidentified non-cannabinoid targets (Ueda et al. 1995b; Starowicz et al. 2013; for a review, see Woodward et al. 2008). An important unanswered question is whether these reactions represent an alternative path for anandamide deactivation (Kim and Alger 2004), provide a mechanism for the generation of distinct classes of lipid mediators (Starowicz et al. 2013; Woodward et al. 2008), or both.

Additional Endogenous Cannabinoid Ligands

In addition to 2-AG and anandamide, other naturally occurring lipid molecules have been shown to bind to and activate cannabinoid receptors. These include noladin ether, an ether-linked analog of 2-AG (Hanus et al. 2001); virodhamine, the ester of arachidonic acid with ethanolamine (Porter et al. 2002); and *N*-arachidonoyl dopamine, an endogenous vanilloid agonist that also exhibits affinity for cannabinoid receptors in vitro (Bisogno et al. 2000). However, the physiological significance of these substances, if any, remains unknown.

Cannabinoid-Based Therapeutics

European and American pharmacopeias of the late nineteenth and early twentieth century listed cannabis as an analgesic, hypnotic, and anticonvulsant (Iversen 2000; Russo 2007). The lawful use of cannabis as a medicine came to a stop in the 1930s, following the introduction in various countries, including the United States, of severe legal restrictions on its sale and use. This scenario has dramatically changed in recent years. As of March 2021, 36 states of the Union, the District of Columbia, and Guam have allowed the medical use of cannabis, quickly leading to a resurgence of its application to a variety of ailments, including glaucoma, loss of appetite, nausea, chronic pain, and muscle spasticity. Most of these indications lack adequate support from controlled clinical studies (Wei and Piomelli 2015), though many find a rational basis in the biology of the endocannabinoid system (Fig. 9). The adult nonmedical use of cannabis is legal in 15 states, the District of Columbia, the Northern Mariana Islands, and Guam. However, the drug's ability to cause




Fig. 9 Possible therapeutic modulation of the endocannabinoid system. The roles played by the endocannabinoid system in the control of a variety of physiological processes and the availability of drugs modulating this system provide multiple opportunities for drug discovery. Pharmacological modulation of the endocannabinoid system can be achieved by direct agonists and antagonists for cannabinoid receptors and by inhibitors targeting enzymes responsible for endocannabinoid inactivation

problematic use (Wei and Piomelli 2015) continues to play a major role in setting the agenda for cannabinoid-based therapeutics.

CB₁ Receptor Agonists

Three currently available medications target cannabinoid receptors (for a review, see Pertwee 2012). Δ^9 -THC itself is marketed under the trade name of *Marinol*[®] and is used in the clinic to increase appetite in anorexic HIV patients and combat nausea caused by cancer chemotherapeutics. A synthetic analog of Δ^9 -THC, *nabilone* (*Cesamet*[®]), is prescribed in Europe for similar indications. The third approved cannabinoid-based medication is a *Cannabis* extract primarily composed of Δ^9 -THC and cannabidiol (Fig. 1a). Commercialized in Canada and several European countries under the name of *nabiximols* (*Sativex*[®]), this extract is utilized as a sublingual spray for the relief of pain and muscle spasticity due to multiple sclerosis and as an adjunctive analgesic treatment in cancer patients (Pertwee 2012).

In addition to Δ^9 -THC and nabilone, various highly potent cannabinoid agonists have been described in the literature (Fig. 1b) (for reviews, see Iversen 2001; Pertwee 2012). The therapeutic utility of these ligands is limited by their CB₁-mediated psychotropic side effects, which also provide the rationale for the illicit use of some of them as an alternative to recreational marijuana (for a review, see Wells and Ott 2011). Products such as *Spice*, *K2*, and *Eclipse* are a blend of various herbs and spices, which have been laced with one of these synthetic cannabinoids. It is generally assumed that their effects are similar to those of Δ^9 -THC, but the preclinical and clinical data supporting this assumption are still limited.

CB₁ Receptor Antagonists

Rimonabant (*Acomplia*[®], previously known as SR141716A) was the first CB₁ antagonist to be developed and remains one of the most extensively studied members of this class of drugs (Mackie 2006) (Fig. 10). It selectively binds to CB₁ receptors




Fig. 10 Chemical structures of CB₁ receptor antagonists. Rimonabant (SR141716) was the first CB₁ antagonist to be reported. It was approved for use as an anti-obesity drug in Europe and other countries but was subsequently withdrawn due to psychiatric side effects. Also shown are the structures of two additional CB₁ antagonists, taranabant and AM251

with nanomolar affinity and, in most experimental settings, it behaves as an inverse agonist (Mackie 2006). (“Inverse agonists” elicit pharmacological responses that are opposite to those exerted by agonists. “Neutral antagonists” (or simply “antagonists”) block the access of agonists to their receptors without producing a response.) An important effect of rimonabant and other CB₁ antagonists is to counteract the regulatory control exerted by endocannabinoid substances on central and peripheral mechanisms of energy conservation (DiPatrizio and Piomelli 2012). In obese animals and humans, this effect translates into significant improvements in lipid profiles, central obesity, and insulin resistance, along with a sustained albeit moderate weight loss (for a review, see Engeli 2012). The therapeutic potential of CB₁ antagonists is limited, however, by the fact that the endocannabinoids can also strongly influence the activity of neural circuits involved in the regulation of stress responses, affect, mood, and motivation (for a review, see Clapper et al. 2009). Indeed, treatment with CB₁ antagonists produces in humans a series of psychiatric adverse events (including anxiety, depression, and suicidal thoughts), which have led to stop their clinical development as anti-obesity medications (Engeli 2012). An alternative approach that is currently under investigation is the use of peripherally restricted antagonists to target CB₁ receptors in the adipose organ, pancreas, and liver. In preclinical models, these receptors have been shown to play important roles in the anti-obesity effects of CB₁ blockade (Tam et al. 2010).

Considering the complex changes in brain circuits and pleomorphic mechanisms underlying problematic substance use, it is not surprising that no unifying theme has been identified for the function of endocannabinoid signaling in these conditions. Nevertheless, it is notable that preclinical and human clinical studies have pointed to a pivotal role for the endocannabinoid system in nicotine addiction. For example, CB₁ antagonists prevent nicotine-induced conditioned place preference and nicotine-induced dopamine release in the nucleus accumbens (Castane et al. 2002; Cohen et al. 2002). These actions suggest that CB₁ receptor blockade may decrease the strength of specific environmental cues associated with nicotine intake. However, there is no clinical evidence supporting the use of CB₁ receptor antagonism in smoking cessation (for a review, see Cahill et al. 2013). It is notable that the endocannabinoid system is also implicated in the reinforcing effects of alcohol, heroin, and cocaine. For example, CB₁ activation enhances alcohol consumption, while CB₁ blockade has the opposite effect. Genetic deletion of the CB₁ receptor reduces alcohol-induced conditioned place preference (Thanos et al. 2005). Likewise, administration of CB₁ antagonists or genetic deletion of CB₁ receptors reduced cocaine-seeking behavior of mice (Soria et al. 2005; Orio et al. 2009; for review, see Maldonado et al. 2006).

CB₂ Receptor Agonists

A particularly attractive feature of selective CB₂ receptor agonists as therapeutics is that they are seemingly devoid of central side effects. Nevertheless, a number of preclinical studies have shown that these agents are highly effective in animal

models of chronic neuropathic pain, peripheral inflammation, and sensitization (Ibrahim et al. 2003; Hohmann et al. 2004). They also appear to be useful in combating cocaine addiction (Xi et al. 2011), through a mechanism that remains unclear, and in counteracting bone loss, which is suggestive of a potential application in osteoporosis. Supporting this theory, a single nucleotide polymorphism (SNP) in the CB₂ receptor gene strongly correlates with osteoporosis in a cohort of women (Karsak et al. 2005).

Endocannabinoid Deactivation Inhibitors

The psychiatric adverse events associated with the use of Δ^9 -THC and its synthetic mimics are an obstacle to broader clinical development. As a potential alternative, the endocannabinoid system offers several opportunities to circumvent such events and possibly achieve adequate therapeutic efficacy. In particular, both FAAH inhibitors and MGL inhibitors have reached clinical testing and are currently being considered for the treatment of a variety of conditions including social anxiety, cannabis use disorder (i.e., dependence and withdrawal), and chronic pain. Intriguing data also suggest a possible application in schizophrenia.

Anxiety The hypothesis that anandamide is an important regulator of stress-coping behaviors was first suggested by animal experiments, which showed that the FAAH inhibitor URB597 decreases isolation-induced ultrasonic vocalizations in rat pups and increases the time spent by adult rats in the open arms of an elevated maze (Kathuria et al. 2003). Subsequent studies found that URB597 also enhances active stress-coping behaviors in mouse and rat models of acute and chronic stress (Gobbi et al. 2005; Bortolato et al. 2007). Other FAAH inhibitors were later shown to exert anxiolytic-like effects that were similar to those of URB597 (Bluett et al. 2014). Such effects are prevented by administration of a CB₁ inverse agonist, an indication that they are due to enhanced anandamide-mediated transmission at CB₁ receptors. Further implicating anandamide in response to stressful stimuli, a study in healthy volunteers showed that the circulating levels of anandamide were elevated after exposing the subjects to a psychosocial stress test (Dlugos et al. 2012). In this context, it is important to point out that URB597 has no rewarding effects in rodents (Gobbi et al. 2005) and is not self-administered by squirrel monkeys (Justinova et al. 2008), marking a clear mechanistic distinction with Δ^9 -THC and suggesting that FAAH inhibitors might be used in the clinic without risk of abuse. Human studies have confirmed that anandamide signaling controls the emotional response to stress, possibly through modulation of prefrontal cortical-amygdala circuits (for a review, see Patel et al. 2017). For example, individuals who carry the non-synonymous FAAH polymorphism C385A, who exhibit higher plasma levels of anandamide, show increased fronto-amygdalar connectivity and cued fear extinction (Dincheva et al. 2015). Moreover, administration of the FAAH inhibitor PF-04457845 to human volunteers was found to improve the recall of fear extinction memories and to attenuate the anxiogenic effects of stress in healthy subjects (Mayo et al. 2020).

Similarly, a structurally different FAAH inhibitor, JNJ-42165279, was shown to dampen activation of several brain structures involved in anxiety – including the amygdala, anterior cingulate, and insula – during an emotion face-processing task (Paulus et al. 2021). The same drug was also tested in a multicenter, placebo-controlled Phase-2 trial in persons with social anxiety disorder. This trial reported statistically detectable signs of efficacy, but the dosage used was deemed insufficient to block FAAH (Schmidt et al. 2021). Further testing in human anxiety and trauma/stressor-related disorders is warranted.

Cannabis Addiction The pharmacological profile of FAAH inhibitors predicts that they should alleviate many of the symptoms experienced by abstinent marijuana addicts – including anxiety, depression, and deterioration of sleep quality (for a review, see Clapper et al. 2009). A randomized double-blind clinical trial aimed at determining the safety and efficacy of the compound PF-04457845, a FAAH inhibitor that is structurally different from URB597, showed that this agent is effective in reducing cannabis use and alleviating cannabis withdrawal symptoms in men (D’Souza et al. 2019). A replication study is ongoing at the time of this writing, and its outcome will likely influence future research directions in other areas of addiction medicine, such as tobacco (Justinova et al. 2015) and cocaine use disorder (Adamczyk et al. 2009; for reviews, see Panlilio et al. 2013; Piomelli 2014).

Pain A large body of preclinical evidence points to the ECS as a critical regulator of pain processing (for reviews, see Soliman et al. 2021). The phenotype of individuals who carry loss-of-function *FAAH* mutations – including C385A and *FAAH-OUT* – have lent support to this conclusion (Greenbaum et al. 2012; Habib et al. 2019), but so far the results of clinical trials have been disappointing (Huggins et al. 2012; Wagenlehner et al. 2017).

Schizophrenia Autoradiography and positron emission tomography studies have shown that CB₁ receptor densities are elevated in cortical and subcortical areas of human subjects with schizophrenia (Wong et al. 2010). These results are sometimes interpreted as suggesting that excessive endocannabinoid transmission might be a causative factor in psychosis (Andreasson et al. 1987), but data from other studies offer an opposing perspective. First, a simplistic “endocannabinoid hypothesis of schizophrenia” is negated by the fact that the CB₁ antagonist rimonabant did not significantly improve disease symptoms in a placebo-controlled clinical trial of subjects with schizophrenia (Meltzer et al. 2004) or in a subsequent double-blind placebo-controlled trial aimed at assessing the impact of the drug on cognitive function in schizophrenic subjects (Boggs et al. 2012). Second, a study in non-medicated first-episode persons with psychosis showed that cerebrospinal levels of anandamide correlate *inversely* with positive and negative symptoms of schizophrenia (Leweke et al. 2007). Third, in a double-blind randomized clinical trial of cannabidiol in acute psychosis, treatment with the drug was accompanied by a substantial increase in circulating anandamide levels, which was significantly associated with clinical improvement (Leweke et al. 2012). Finally, in patients in the

prodromal states of schizophrenia, lower cerebrospinal levels of anandamide were linked with higher risk of an earlier transition to psychosis (Koethe et al. 2009). These results are consistent with animal studies suggesting that anandamide signaling in the basal ganglia of rats and mice may be part of a negative feedback loop that offsets the effects of excessive dopaminergic activity (for a review, see van der Stelt and Di Marzo 2003). Thus, a substantial number of findings support the conclusion that anandamide may act as a homeostatic controller of dopamine neurotransmission and a protective signal in schizophrenia. A corollary of this hypothesis is that FAAH inhibitors may be beneficial in psychosis and, possibly, in other mental disorders in which hyperactive dopamine transmission might be implicated (e.g., Tourette's syndrome).

Outlook

Research on the endocannabinoid system has greatly expanded our understanding on these unique signaling molecules and the roles they play in health and disease. Information gleaned from studies on cannabis has illuminated how Δ^9 -THC and other exogenous cannabinoids hijack the endocannabinoid signaling system, leading to unwanted effects but at the same time providing promising opportunities for therapeutic intervention. While important questions remain, it is nevertheless clear that the therapeutic potential of endocannabinoid modulation calls for further basic and clinical investigation.

References

- Adamczyk P, McCreary AC, Przegalinski E, Mierzejewski P, Bienkowski P, Filip M (2009) The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. *J Physiol Pharmacol* 60(3):119–125
- Adams R (1942, February 19) Marihuana: Harvey lecture. *Bull N Y Acad Med* 18(11):705–730
- Allen AC, Gammon CM, Ousley AH, McCarthy KD, Morell P (1992) Bradykinin stimulates arachidonic acid release through the sequential actions of an sn-1 diacylglycerol lipase and a monoacylglycerol lipase. *J Neurochem* 58(3):1130–1139
- Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. *Lancet* 2:1483–1486
- Bell RL, Kennerly DA, Stanford N, Majerus PW (1979) Diglyceride lipase: a pathway for arachidonate release from human platelets. *Proc Natl Acad Sci U S A* 76(7):3238–3241
- Beltramo M, Piomelli D (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylethanolamide. *Neuroreport* 11(6):1231–1235
- Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* 277(5329):1094–1097
- Bennett CF, Balcerek JM, Varrichio A, Croke ST (1988) Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. *Nature* 334(6179):268–270
- Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) *N*-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of

- anandamide inactivation with cannabimimetic activity in vitro and in vivo. *Biochem J* 351 (Pt 3):817–824
- Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* 163(3):463–468
- Blankman JL, Simon GM, Cravatt BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol* 14(12):1347–1356
- Blankman JL, Long JZ, Trauger SA, Siuzdak G, Cravatt BF (2013) ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC. *Proc Natl Acad Sci U S A* 110(4):1500–1505
- Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S (2014) Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. *Transl Psychiatry* 4:e408
- Boggs DL, Kelly DL, McMahan RP, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW (2012) Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. *Schizophr Res* 134(2–3):207–210
- Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. *Biol Psychiatry* 62(10):1103–1110
- Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. *J Neurosci* 16(12):3934–3942
- Cadas H, di Tomaso E, Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, *N*-arachidonoyl phosphatidylethanolamine, in rat brain. *J Neurosci* 17(4):1226–1242
- Cahill K, Stevens S, Perera R, Lancaster T (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 5:CD009329. Review
- Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. *Neuropharmacology* 43:857–867
- Castillo PE, Younts TJ, Chávez AE, Hashimoto-dani Y (2012) Endocannabinoid signaling and synaptic function. *Neuron* 76(1):70–81. Review
- Chevalere V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. *Ann Rev Neurosci* 29:37–76. Review
- Clapper JR, Mangieri RA, Piomelli D (2009) The endocannabinoid system as a target for the treatment of cannabis dependence. *Neuropharmacology* 56(Suppl 1):235–243. Review
- Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. *Behav Pharmacol* 13:451–463
- Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature* 384(6604):83–87
- Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. *Proc Natl Acad Sci U S A* 98(16):9371–9376
- Dennis EA, Deems RA, Harkewicz R, Quehenberger O, Brown HA, Milne SB, Myers DS, Glass CK, Hardiman G, Reichart D, Merrill AH Jr, Sullards MC, Wang E, Murphy RC, Raetz CR, Garrett TA, Guan Z, Ryan AC, Russell DW, McDonald JG, Thompson BM, Shaw WA, Sud M, Zhao Y, Gupta S, Maurya MR, Fahy E, Subramaniam S (2010) A mouse macrophage lipidome. *J Biol Chem* 285(51):39976–39985
- Desarnaud F, Cadas H, Piomelli D (1995) Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. *J Biol Chem* 270(11):6030–6035

- Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol* 34(5):605–613
- Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258(5090):1946–1949
- Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* 372(6507):686–691
- Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC, Ra S, Gray JM, Yang R, DeGruccio AM, Huang C, Cravatt BF, Glatt CE, Hill MN, Casey BJ, Lee FS (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. *Nat Commun* 6: 6395. <https://doi.org/10.1038/ncomms7395>. PMID: 25731744; PMCID: PMC4351757
- Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci U S A* 99(16):10819–10824
- Dinh TP, Kathuria S, Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol Pharmacol* 66(5):1260–1264
- DiPatrizio NV, Piomelli D (2012) The thrifty lipids: endocannabinoids and the neural control of energy conservation. *Trends Neurosci* 35(7):403–411. Review
- DiPatrizio NV, Piomelli D (2015) Intestinal lipid-derived signals that sense dietary fat. *J Clin Invest* 125(3):891–898. Review
- Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H (2012) Acute stress increases circulating anandamide and other *N*-acylethanolamines in healthy humans. *Neuropsychopharmacology* 37(11):2416–2427
- D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. *Lancet Psychiatry* 6(1):35–45. [https://doi.org/10.1016/S2215-0366\(18\)30427-9](https://doi.org/10.1016/S2215-0366(18)30427-9). Epub 2018 Dec 6. PMID: 30528676
- Egertová M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. *Proc Biol Sci* 265(1410):2081–2085
- Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. *Neuroscience* 119(2):481–496
- Engeli S (2012) Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. *Handb Exp Pharmacol* 209:357–381. Review
- Farooqui AA, Horrocks LA, Farooqui T (2000) Deacylation and reacylation of neural membrane glycerophospholipids. *J Mol Neurosci* 14(3):123–135. Review
- Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. *Proc Natl Acad Sci U S A* 101(23):8756–8761. <https://doi.org/10.1073/pnas.0400997101>. Epub 2004 May 11. PMID: 15138300; PMCID: PMC423268
- Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev* 83(3):1017–1066. Review
- Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature* 425(6953): 90–93

- Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. *J Am Chem Soc* 86:1646–1647
- Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat Neurosci* 2(4):358–363
- Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proc Natl Acad Sci U S A* 102(51):18620–18625
- González S, Cebeira M, Fernández-Ruiz J (2005) Cannabinoid tolerance and dependence: a review of studies in laboratory animals. *Pharmacol Biochem Behav* 81(2):300–318. Review
- Greenbaum L, Tegeger I, Barhum Y, Melamed E, Roditi Y, Djaldetti R (2012) Contribution of genetic variants to pain susceptibility in Parkinson disease. *Eur J Pain* 16(9):1243–1250. <https://doi.org/10.1002/j.1532-2149.2012.00134.x>. Epub 2012 Apr 4. PMID: 22473870
- Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur J Neurosci* 20(2):441–458
- Habib AM, Okorokov AL, Hill MN, Bras JT, Lee MC, Li S, Gossage SJ, van Drimmelen M, Morena M, Houlden H, Ramirez JD, Bennett DLH, Srivastava D, Cox JJ (2019) Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. *Br J Anaesth* 123(2):e249–e253. <https://doi.org/10.1016/j.bja.2019.02.019>. Epub 2019 Mar 28. PMID: 30929760; PMCID: PMC6676009
- Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. *Proc Natl Acad Sci U S A* 98(7):3662–3665
- Harizi H, Corcuff JB, Gualde N (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med* 14(10):461–469. Review
- Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A* 87(5):1932–1936
- Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB (1995) Characterization of the kinetics and distribution of *N*-arachidonyl ethanolamine (anandamide) hydrolysis by rat brain. *Biochim Biophys Acta* 1257(3):249–256
- Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry* 17(6):642–649
- Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A (2004) Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. *J Pharmacol Exp Ther* 308:446–453
- Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. *Nature* 435(7045):1108–1112
- Huggins JP, Smart TS, Langman S, Taylor L, Young T (2012) An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. *Pain* 153(9):1837–1846. <https://doi.org/10.1016/j.pain.2012.04.020>. Epub 2012 Jun 21. PMID: 22727500
- Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J et al (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. *Proc Natl Acad Sci U S A* 100:10529–10533
- Iversen LL (2000) The science of marijuana. Oxford University Press, Oxford
- Iversen L (2001) Cannabinoids in pain management. Few well controlled trials of cannabis exist for systemic review. *BMJ* 323(7323):1250

- Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. *Mol Pharmacol* 68(5):1196–1202
- Jung KM, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D (2007) A key role for diacylglycerol lipase- α in metabotropic glutamate receptor-dependent endocannabinoid mobilization. *Mol Pharmacol* 72(3):612–621
- Jung KM, Clapper JR, Fu J, D'Agostino G, Guijarro A, Thongkham D, Avanesian A, Astarita G, DiPatrizio NV, Frontini A, Cinti S, Diano S, Piomelli D (2012a) 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. *Cell Metab* 15(3):299–310
- Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D, Manzoni OJ (2012b) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat Commun* 3:1080
- Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. *Biol Psychiatry* 64(11):930–937
- Justinova Z, Panlilio LV, Moreno-Sanz G, Redhi GH, Auber A, Secci ME, Mascia P, Bandiera T, Armirotti A, Bertorelli R, Chefer SI, Barnes C, Yasar S, Piomelli D, Goldberg SR (2015) Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. *Neuropsychopharmacology* 40(9):2185–2197
- Kano M, Ohno-Shosaku T, Hashimoto-dani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. *Physiol Rev* 89(1):309–380. Review
- Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. *J Biol Chem* 272(43):27218–27223
- Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A (2005) Cannabinoid receptor type 2 gene is associated with human osteoporosis. *Hum Mol Genet* 14(22):3389–3396
- Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med* 9(1):76–81
- Katona I, Freund TF (2012) Multiple functions of endocannabinoid signaling in the brain. *Annu Rev Neurosci* 35:529–558. Review
- Katona I, Sperlág B, Sík A, Káfalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. *J Neurosci* 19(11):4544–4558
- Katona I, Urbán GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. *J Neurosci* 26(21):5628–5637
- Kempe K, Hsu FF, Bohrer A, Turk J (1996) Isotope dilution mass spectrometric measurements indicate that arachidonyl ethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. *J Biol Chem* 271(29):17287–17295
- Kim J, Alger BE (2004) Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. *Nat Neurosci* 7(7):697–698
- Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Piomelli D, Leweke FM (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. *Br J Psychiatry* 194(4):371–372
- Kozak KR, Rowlinson SW, Marnett LJ (2000) Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. *J Biol Chem* 275(43):33744–33749

- Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. *Schizophr Res* 94(1–3):29–36
- Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Transl Psychiatry* 2:e94
- Li CM, Hong SB, Kopal G, He X, Linke T, Hou WS, Koch J, Gatt S, Sandhoff K, Schuchman EH (1998) Cloning and characterization of the full-length cDNA and genomic sequences encoding murine acid ceramidase. *Genomics* 50(2):267–274
- Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G (2006) A biosynthetic pathway for anandamide. *Proc Natl Acad Sci U S A* 103(36):13345–13350
- Lourenço J, Matias I, Marsicano G, Mulle C (2011) Pharmacological activation of kainate receptors drives endocannabinoid mobilization. *J Neurosci* 31(9):3243–3248
- LoVerre J, La Rana G, Russo R, Calignano A, Piomelli D (2005) The search for the palmitoylethanolamide receptor. *Life Sci* 77(14):1685–1698. Review
- Mackie K (2006) Cannabinoid receptors as therapeutic targets. *Annu Rev Pharmacol Toxicol* 46:101–122. Review
- Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (2015) Structure of human *N*-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. *Structure* 23(3):598–604
- Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. *Trends Neurosci* 29:225–232. Review
- Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, Li W, Xu C, Möller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. *Nat Neurosci* 13(8):951–957
- Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. *Eur J Neurosci* 11(12):4213–4225
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 346(6284):561–564
- Mátyás F, Urbán GM, Watanabe M, Mackie K, Zimmer A, Freund TF, Katona I (2008) Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. *Neuropharmacology* 54(1):95–107
- Mayo LM, Asratian A, Lindé J, Morena M, Haataja R, Hammar V, Augier G, Hill MN, Heilig M (2020) Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled Experimental Medicine Trial *Biol Psychiatry* 87(6):538–547. <https://doi.org/10.1016/j.biopsych.2019.07.034>. Epub 2019 Aug 13. PMID: 31590924
- McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. *Ann Rev Biochem* 74:411–432. Review
- Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50(1):83–90
- Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. *Am J Psychiatry* 161(6):975–984
- Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 365(6441):61–65
- Nyilas R, Gregg LC, Mackie K, Watanabe M, Zimmer A, Hohmann AG, Katona I (2009) Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. *Eur J Neurosci* 29(10):1964–1978

- Ogura Y, Parsons WH, Kamat SS, Cravatt BF (2016) A calcium-dependent acyltransferase that produces *N*-acyl phosphatidylethanolamines. *Nat Chem Biol* 12(9):669–671. <https://doi.org/10.1038/nchembio.2127>. Epub 2016 Jul 11. PMID: 27399000; PMCID: PMC4990470
- Orio L, Edwards S, George O, Parsons LH, Koob GF (2009) A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. *J Neurosci* 29:4846–4857
- Panlilio LV, Justinova Z, Goldberg SR (2013) Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. *Pharmacol Ther* 138(1):84–102. Review
- Park JH, Schuchman EH (2006) Acid ceramidase and human disease. *Biochim Biophys Acta* 1758(12):2133–2138. Review
- Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A (2017) The endocannabinoid system as a target for novel anxiolytic drugs. *Neurosci Biobehav Rev* 76(Pt A):56–66. <https://doi.org/10.1016/j.neubiorev.2016.12.033>. PMID: 28434588; PMCID: PMC5407316
- Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR (2021) The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. *Neuropsychopharmacology* 46(5):1011–1019. <https://doi.org/10.1038/s41386-020-00936-w>. Epub 2020 Dec 17. PMID: 33335310
- Pertwee RG (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. *Philos Trans R Soc Lond Ser B Biol Sci* 367(1607):3353–3363. Review
- Pete MJ, Ross AH, Exton JH (1994) Purification and properties of phospholipase A1 from bovine brain. *J Biol Chem* 269(30):19494–19500
- Piomelli D (2003) The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* 4(11):873–884. Review. No abstract available
- Piomelli D (2014) More surprises lying ahead. The endocannabinoids keep us guessing. *Neuropharmacology* 76 Pt B:228–234. (Review)
- Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A (1999) Structural determinants for recognition and translocation by the anandamide transporter. *Proc Natl Acad Sci U S A* 96(10):5802–5807
- Piomelli D, Astarita G, Rapaka R (2007) A neuroscientist's guide to lipidomics. *Nat Rev Neurosci* 8(10):743–754. Review
- Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J Pharmacol Exp Ther* 301(3):1020–1024
- Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D (2013) Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. *Sci Rep* 3:1035
- Russo EB (2007) History of cannabis and its preparations in saga, science, and sobriquet. *Chem Biodivers* 4(8):1614–1648
- Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D (2013) Antinociceptive effects of the *N*-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. *Pain* 154(3):350–360
- Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, Schmid HH (1995) Occurrence and postmortem generation of anandamide and other long-chain *N*-acylethanolamines in mammalian brain. *FEBS Lett* 375(1–2):117–120
- Schmidt ME, Liebowitz MR, Stein MB, Grunfeld J, Van Hove I, Simmons WK, Van Der Ark P, Palmer JA, Saad ZS, Pemberton DJ, Van Nueten L, Drevets WC (2021) The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study. *Neuropsychopharmacology* 46(5):1004–1010. <https://doi.org/10.1038/s41386-020-00888-1>. Epub 2020 Oct 18. PMID: 33070154
- Shulga YV, Topham MK, Epand RM (2011) Regulation and functions of diacylglycerol kinases. *Chem Rev* 111(10):6186–6208. Review
- Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-*N*-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. *J Biol Chem* 281(36):26465–26472

- Simon GM, Cravatt BF (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho- *N*-acyl ethanolamine precursors in mouse brain. *J Biol Chem* 283(14):9341–9349
- Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, Segelcke D, Sena C, Thomas J, Vollert J, Wever K, Alaverdyan H, Barakat A, Barthlow T, Harris Bozer AL, Davidson A, Diaz-delCastillo M, Dolgorukova A, Ferdousi MI, Healy C, Hong S, Hopkins M, James A, Leake HB, Malewicz NM, Mansfield M, Mardon AK, Mattimoe D, McLoone DP, Noes-Holt G, Pogatzki-Zahn EM, Power E, Pradier B, Romanos-Sirakis E, Segelcke A, Vinagre R, Yanes JA, Zhang J, Zhang XY, Finn DP, Rice ASC. (2021, 15 March) A systematic review and meta-analysis of cannabis-based medicines, cannabinoids and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. *Pain*. <https://doi.org/10.1097/j.pain.0000000000002269>. Epub ahead of print. PMID: 33729209
- Soria G, Mendizábal V, Touriño C, Robledo P, Ledent C, Parmentier M, Maldonado R, Valverde O (2005) Lack of CB1 cannabinoid receptor impairs cocaine self-administration. *Neuropsychopharmacology* 30:1670–1680
- Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V (2013) Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. *PLoS One* 8(4):e60040
- Steffens M, Feuerstein TJ, van Velthoven V, Schnierle P, Knörle R (2003) Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. *Naunyn Schmiedeberg's Arch Pharmacol* 368(5):432–436
- Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. *Eur J Pharmacol* 425(3):189–196
- Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388(6644):773–778
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* 215(1):89–97
- Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. *J Clin Invest* 120(8):2953–2966
- Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005) Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. *Behav Brain Res* 164(2):206–213
- Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. *J Neurosci Res* 50(6):1047–1052
- Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995a) Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. *J Biol Chem* 270(40):23823–23827
- Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K et al (1995b) Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. *Biochim Biophys Acta* 1254(2):127–134
- Ueda N, Tsuboi K, Uyama T (2010) *N*-acylethanolamine metabolism with special reference to *N*-acylethanolamine-hydrolyzing acid amidase (NAAA). *Prog Lipid Res* 49(4):299–315. Review
- Ueda N, Tsuboi K, Uyama T (2013) Metabolism of endocannabinoids and related *N*-acylethanolamines: canonical and alternative pathways. *FEBS J* 280(9):1874–1894. Review

- van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. *Eur J Pharmacol* 480(1–3):133–150. Review
- Wagenlehner FME, van Til JWO, Houbiers JGA, Martina RV, Cerneus DP, Melis JHJM, Majek A, Vjaters E, Urban M, Ramonas H, Shoskes DA, Nickel JC (2017) Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. *Urology* 103:191–197. <https://doi.org/10.1016/j.urology.2017.02.029>. Epub 2017 Feb 27. PMID: 28254462
- Wei D, Piomelli D (2015) Cannabinoid-based drugs: potential applications in addiction and other mental disorders. *Focus* 13(3):307–316. Review
- Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, Gall CM, Piomelli D (2015) Endocannabinoid signaling mediates oxytocin-driven social reward. *Proc Natl Acad Sci U S A* 112(45):14084–14089. <https://doi.org/10.1073/pnas.1509795112>. Epub 2015 Oct 26. PMID: 26504214; PMCID: PMC4653148
- Wells DL, Ott CA (2011) The “new” marijuana. *Ann Pharmacother* 45(3):414–417. Review
- Wollner HJ, Matchett JR, Levine J, Loewe S (1942) Isolation of a physiologically active tetrahydrocannabinol from cannabis Sativa resin. *J Am Chem Soc* 64(1):26–29
- Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, Ye W, Dannals RF, Ravert HT, Nandi A, Rahmim A, Ming JE, Grachev I, Roy C, Cascella N (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [¹¹C]OMAR. *NeuroImage* 52(4):1505–1513
- Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW (2008) The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. *Pharmacol Ther* 120(1):71–80. Review
- Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. *Nat Neurosci* 14(9):1160–1166
- Zhu C, Solorzano C, Sahar S, Realini N, Fung E, Sassone-Corsi P, Piomelli D (2011) Pro-inflammatory stimuli control *N*-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. *Mol Pharmacol* 79(4):786–792